X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1346) 1346
Publication (227) 227
Book Review (13) 13
Book Chapter (3) 3
Magazine Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1127) 1127
hiv infections - drug therapy (885) 885
lopinavir (828) 828
index medicus (746) 746
male (725) 725
female (704) 704
adult (627) 627
infectious diseases (621) 621
ritonavir - administration & dosage (546) 546
ritonavir (463) 463
hiv (445) 445
middle aged (403) 403
pharmacology & pharmacy (394) 394
anti-hiv agents - administration & dosage (391) 391
hiv protease inhibitors - administration & dosage (389) 389
ritonavir - therapeutic use (362) 362
pyrimidinones - administration & dosage (357) 357
drug therapy, combination (342) 342
immunology (331) 331
lopinavir/ritonavir (330) 330
antiretroviral therapy (316) 316
protease inhibitors (313) 313
anti-hiv agents - therapeutic use (290) 290
hiv protease inhibitors - therapeutic use (284) 284
hiv infections - virology (280) 280
viral load (280) 280
treatment outcome (268) 268
pharmacokinetics (267) 267
drug therapy (242) 242
pyrimidinones - therapeutic use (239) 239
ritonavir - adverse effects (229) 229
dosage and administration (221) 221
virology (221) 221
drug administration schedule (216) 216
antiviral agents (215) 215
hiv infection (210) 210
hiv-1 - drug effects (207) 207
ritonavir - pharmacokinetics (206) 206
drug combinations (204) 204
lopinavir - administration & dosage (203) 203
hiv protease inhibitors - adverse effects (202) 202
microbiology (202) 202
human immunodeficiency virus--hiv (184) 184
therapy (182) 182
cd4 lymphocyte count (175) 175
tenofovir (172) 172
drug interactions (168) 168
hiv protease inhibitors - pharmacokinetics (166) 166
aids/hiv (165) 165
anti-hiv agents - adverse effects (165) 165
research (165) 165
anti-hiv agents - pharmacokinetics (158) 158
pyrimidinones - adverse effects (153) 153
antiretroviral drugs (151) 151
young adult (150) 150
adolescent (149) 149
atazanavir sulfate (149) 149
aids (146) 146
hiv-1 (146) 146
safety (145) 145
antiretroviral therapy, highly active (143) 143
efficacy (142) 142
highly active antiretroviral therapy (139) 139
health aspects (135) 135
pyrimidinones - pharmacokinetics (130) 130
atazanavir (129) 129
efavirenz (122) 122
lopinavir - therapeutic use (120) 120
protease inhibitor (116) 116
hiv-1-infected patients (115) 115
article (114) 114
virus diseases (114) 114
darunavir (112) 112
pyridines - administration & dosage (112) 112
adenine - analogs & derivatives (108) 108
analysis (105) 105
oligopeptides - administration & dosage (105) 105
combination (103) 103
human immunodeficiency virus (103) 103
prospective studies (103) 103
aged (102) 102
hiv infections - blood (101) 101
hiv-infected patients (100) 100
rna, viral - blood (99) 99
animals (97) 97
child (96) 96
ritonavir - pharmacology (95) 95
care and treatment (94) 94
active antiretroviral therapy (93) 93
lamivudine (91) 91
reverse transcriptase inhibitors - administration & dosage (91) 91
risk factors (91) 91
drugs (89) 89
emtricitabine (88) 88
hiv infections - complications (88) 88
hiv-1 - genetics (87) 87
lopinavir - pharmacokinetics (87) 87
antiretroviral therapy, highly active - methods (86) 86
infant (86) 86
lopinavir-ritonavir (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1286) 1286
Spanish (31) 31
German (21) 21
Japanese (5) 5
French (4) 4
Russian (4) 4
Chinese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2014, Volume 9, Issue 9, p. e105653
Background: A network meta-analysis can provide estimates of relative efficacy for treatments not directly studied in head-to- head randomized controlled... 
REVERSE-TRANSCRIPTASE INHIBITOR | ANTIRETROVIRAL-NAIVE | TENOFOVIR DISOPROXIL FUMARATE | MULTIDISCIPLINARY SCIENCES | DAILY DARUNAVIR/RITONAVIR | CO-FORMULATED ELVITEGRAVIR | HIV TYPE-1 INFECTION | DOUBLE-BLIND | ONCE-DAILY ATAZANAVIR/RITONAVIR | INITIAL TREATMENT | TWICE-DAILY LOPINAVIR/RITONAVIR | HIV-1 | Lamivudine - administration & dosage | Rilpivirine | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | HIV Infections - immunology | Time Factors | Lipids - blood | Antiretroviral Therapy, Highly Active - methods | Raltegravir Potassium | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Treatment Outcome | CD4 Lymphocyte Count | Adenine - administration & dosage | Randomized Controlled Trials as Topic | Organophosphonates - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Lopinavir - administration & dosage | HIV Infections - drug therapy | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | RNA | Low density lipoproteins | Analysis | DNA polymerases | Triglycerides | HIV (Viruses) | Drug therapy | HIV infection | Backbone | Lipoproteins (low density) | RNA-directed DNA polymerase | Identification methods | Ritonavir | Clinical trials | Efavirenz | Impact analysis | Literature reviews | Randomization | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Mathematical models | Safety | All terrain vehicles | Medical research | Antiretroviral drugs | Sensitivity analysis | Effectiveness | Lopinavir | Lamivudine | Ribonucleic acid--RNA | Patients | Cholesterol | CD4 antigen | Studies | Inhibitors | Abacavir | Nucleosides | Bayesian analysis | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2008, Volume 52, Issue 7, pp. 569 - 576
Journal Article
AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9534, pp. 476 - 482
Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety... 
MEDICINE, GENERAL & INTERNAL | THERAPY | NAIVE PATIENTS | RECOMMENDATIONS | EFAVIRENZ | TENOFOVIR DF | RESISTANCE | AIDS | SOCIETY-USA PANEL | LOPINAVIR/RITONAVIR | NELFINAVIR | Dideoxynucleosides - administration & dosage | Organophosphates - administration & dosage | Lamivudine - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | Humans | Lopinavir | Pyrimidinones - therapeutic use | Organophosphates - therapeutic use | Carbamates - administration & dosage | HIV Protease Inhibitors - administration & dosage | HIV-1 - genetics | Reverse Transcriptase Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Sulfonamides - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | HIV Infections - drug therapy | Dideoxynucleosides - therapeutic use | Pyrimidinones - administration & dosage | Reverse Transcriptase Inhibitors - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Sulfonamides - administration & dosage | Dosage and administration | Protease inhibitors | Comparative analysis | Drug therapy | HIV infection | Antiviral agents | Research | Drug therapy, Combination | Health aspects | Anti-HIV agents | Antiretroviral drugs | Human immunodeficiency virus--HIV | Samples | Clinical trials | Comparative studies | Clinical medicine | Disease control
Journal Article
Journal Article
AIDS (London, England), ISSN 0269-9370, 2013, Volume 27, Issue 5, pp. 803 - 813
To estimate the incidence of and risk factors for modifications to first antiretroviral therapy (ART) regimen, treatment interruption and death. A total of 21... 
HIV/AIDS | FRENCH-HOSPITAL-DATABASE | INFECTIOUS DISEASES | competing-risk method | VIROLOGICAL TREATMENT FAILURE | survival | AIDS | COMPETING RISKS | IMMUNOLOGY | DISCONTINUATION | switch | PROTEASE INHIBITOR | antiretroviral | VIROLOGY | ACTIVE ANTIRETROVIRAL THERAPY | interruption | SOCIETY-USA PANEL | INFECTED PATIENTS | COHORT | HIV-1 | United States - epidemiology | Lamivudine - administration & dosage | Humans | HIV Seropositivity - mortality | HIV Seropositivity - drug therapy | Nevirapine - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Adenine - adverse effects | Time Factors | Deoxycytidine - adverse effects | HIV Infections - mortality | Dideoxynucleosides - adverse effects | Antiretroviral Therapy, Highly Active - methods | Dideoxynucleosides - administration & dosage | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Risk Factors | Organophosphonates - adverse effects | Europe - epidemiology | Benzoxazines - adverse effects | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Lopinavir - administration & dosage | HIV Infections - drug therapy | Nevirapine - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Lopinavir - adverse effects | Cohort Studies
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2008, Volume 359, Issue 21, pp. 2233 - 2244
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 03/2010, Volume 53, Issue 3, pp. 323 - 332
BACKGROUND:Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily lopinavir/ritonavir over 48 weeks, with less gastrointestinal... 
CASTLE study | HIV-1 | Combination antiretroviral therapy | Atazanavir/ritonavir | Treatment-naive patients | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | ADULTS | IMMUNOLOGY | REGIMENS | ADHERENCE | HIV-INFECTED PATIENTS | THERAPY | DIDANOSINE | EFAVIRENZ | DRUGS | atazanavir/ritonavir | SAQUINAVIR/RITONAVIR | combination antiretroviral therapy | treatment-naive patients | Humans | Middle Aged | Male | RNA, Viral - blood | Oligopeptides - adverse effects | Viral Load | Anti-HIV Agents - administration & dosage | Tenofovir | Young Adult | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | HIV-1 - isolation & purification | Lipids - blood | Aged, 80 and over | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Antiretroviral Therapy, Highly Active - methods | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Ritonavir - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Lopinavir | Pyrimidinones - adverse effects | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Aged | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Deoxycytidine - analogs & derivatives
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 10/2011, Volume 53, Issue 8, pp. 807 - 816
Background. We compared 3 years of antiretroviral therapy with raltegravir or efavirenz as part of a combination regimen in the ongoing STARTMRK study of... 
HIV/AIDS | Antiretrovirals | Fasting | HIV | Body fat | Response rates | Viruses | Lipids | Fats | Virology | HIV 1 | INFECTIOUS DISEASES | RESISTANT HIV-1 INFECTION | MULTICENTER | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | THERAPY | DOUBLE-BLIND | LOPINAVIR/RITONAVIR | SUBGROUP | Humans | Male | RNA, Viral - blood | Viral Load | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Adenine - adverse effects | HIV-1 - isolation & purification | Adult | Deoxycytidine - adverse effects | Female | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Absorptiometry, Photon | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Usage | Drug utilization | HIV patients | Dosage and administration | Drug therapy, Combination | Drug therapy | Efavirenz | Raltegravir
Journal Article